Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Articles

Looking Ahead and Key Takeaways

November 20th 2024

Elizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.

Optimizing Regimens and Managing Adverse Events in TIE NDMM

November 20th 2024

Elizabeth O’Donnell, MD, comments on specific patient subgroups, such as frail or high-risk individuals, who benefit most from particular regimens. She discusses adverse events observed in combination therapies for transplant-ineligible patients with newly diagnosed multiple myeloma and shares her approaches to managing these adverse effects in clinical practice.

Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

November 20th 2024

Elizabeth O’Donnell, MD, comments on how the aforementioned trials have influenced the treatment landscape for transplant-ineligible patients with newly diagnosed multiple myeloma and discusses situations in which she favors triplet therapy over quadruplet therapy for these patients.

Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

November 20th 2024

Elizabeth O’Donnell, MD, provides a brief overview of key findings from the MAIA, IMROZ, BENEFIT, and CEPHEUS trials, highlighting significant developments in the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.

Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

November 20th 2024

Elizabeth O’Donnell, MD, discusses the key considerations when choosing frontline therapy for transplant-ineligible patients with newly diagnosed multiple myeloma and how factors such as frailty, age, and performance status influence the decision-making process.

Expanding Cancer Screening: The Future of Blood-Based Testing

November 21st 2023

Closing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.

Future of Multi-Cancer Early Detection: A Recap and Horizon

November 21st 2023

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

Moonshot Cancer Initiative and MCED Consortium: Advancing Cancer Detection

November 14th 2023

Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.

Future Needs and Challenges of Multi-Cancer Early Detection Tests

November 14th 2023

Implementation challenges and the importance of equitable access in the future of multi-cancer early detection tests.

Efficiency in Diagnostic Resolution: Imaging vs. Molecular Tissue of Origin

November 7th 2023

Shared insight into the efficiency of diagnostic resolution approaches, comparing imaging-based and molecular tissue of origin strategies in multi-cancer early detection testing.

Advancing Cancer Detection With the ASCEND Trial: Key Objectives and Rationale

November 7th 2023

Expert perspectives about the ASCEND trial, its study design, and the critical role it plays in developing advanced cancer detection methods.

Advancements in Multi-Biomarker Cancer Testing

October 31st 2023

Key opinion leaders review the rationale behind multi-biomarker approaches and how they're shaping the future of cancer detection and research.

Cancer Screening Breakthroughs: Implications for Clinical Practice

October 31st 2023

Discover the potential clinical implications of groundbreaking cancer screening studies, DETECT-A and PATHFINDER, and the evolving landscape of multi-cancer early detection.

Latest Insights from the PATHFINDER Study: Cancer Detection Advancements

October 24th 2023

Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.

DETECT-A Study: Advancements in Early Cancer Detection

October 24th 2023

Shared insight into findings of the DETECT-A study, a prospective interventional trial, covering feasibility, safety, and performance of multicancer early detection tests in a healthcare system setting.

Addressing Healthcare Inequity With Accessible Multicancer Early Detection

October 17th 2023

The potential of MCED testing to reduce health inequities and an examination of accessibility, including FDA approval, physician education, patient awareness, affordability, and logistical support.

The Transformative Potential of Multicancer Early Detection Testing

October 17th 2023

Expert panelists delve into multicancer early detection testing and discuss its potential to revolutionize cancer screening, close healthcare gaps, and complement standard care approaches.

Multiple Myeloma: Unmet Needs and Future Directions in Care

August 8th 2023

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

August 8th 2023

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Combination Strategies With Bispecifics in Multiple Myeloma

August 1st 2023

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.